Key Pfizer-Sponsored Data Presentations at the European Society for - - PDF document

1

Key Pfizer-Sponsored Data Presentations at the European Society for Medical Oncology (ESMO) Annual Meeting 2018 The embargo on data featured in a poster display session will lift on Tuesday, October 9, at 00:05 CEST. The embargo on data presented as a proffered paper (oral) or poster discussion will lift on Friday, October 19, at 12:00 CEST. Avelumab: (LBA6_PR) JAVELIN Renal 101: a randomized, phase 3 study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). Robert J. Motzer. Sunday, October 21. Session Type: Proffered

• Paper. Presentation Time: 17:20 - 17:35 CEST. Location: Hall A2 – Room 18.

(Abstract 1282P) Responder analysis based on patient-reported outcomes (PROs) and clinical endpoints (CEPs) in patients with metastatic merkel cell carcinoma (mMCC) treated with avelumab. Sandra P. D'Angelo. Sunday, October 21. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 1290P) Avelumab in European patients with metastatic merkel cell carcinoma (mMCC): experience from an ad hoc expanded access program. Paul Nathan. Sunday, October 21. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 1291P) Cost-effectiveness of avelumab vs standard care for the treatment of patients with metastatic merkel cell carcinoma (mMCC). Murtuza Bharmal. Sunday, October 21. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 659P) Avelumab (anti–PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated results from the phase 1b JAVELIN Solid Tumor JPN trial. Toshihiko Doi. Sunday, October 21. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 877P) First-line or second-line avelumab monotherapy in patients with advanced renal cell carcinoma (aRCC) enrolled in the phase 1b JAVELIN Solid Tumor trial. Ulka N. Vaishampayan. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 1241TiP) JAVELIN PARP Medley: a phase 1b/2 study of avelumab (anti–PD-L1) plus talazoparib in locally advanced or metastatic solid tumors. Timothy A. Yap. Saturday, October 20. Session Type: Poster. Presentation Time: 12:30 – 13:30 CEST. Location: Hall A3. Axitinib: (Abstract 863O) Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial

• results. Marine Gross-Goupil. Saturday, October 20. Session Type: Proffered Paper. Presentation Time: 9:15 – 10:45
• CEST. Location: Hall A1 – Room 17.

Bosutinib: (Abstract 1033P) Efficacy and safety of bosutinib vs imatinib in Indian and non-Indian patients with newly diagnosed chronic phase chronic myeloid leukemia: subgroup analysis from the BELA trial. Hemant Malhotra. Saturday, October 20. Session Type: Poster. Presentation Time: 12:30 – 13:30 CEST. Location: Hall A3.

2

Crizotinib: (Abstract 1396P) Efficacy and safety of crizotinib in previously treated patients with ALK+ advanced non-small- cell lung cancer (NSCLC) aged ≥65 years. Denis Moro-Sibilot. Saturday, October 20. Session Type: Poster. Presentation Time: 12:30 – 13:30 CEST. Location: Hall A3. (Abstract 1397P) Long-term safety of crizotinib in previously treated patients with ALK-positive advanced/metastatic non-small-cell lung cancer (NSCLC). Lucio Crinò. Saturday, October 20. Session Type: Poster. Presentation Time: 12:30 – 13:30 CEST. Location: Hall A3. Enzalutamide: (Abstract 807P) Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: results from the PROSPER study. Bertrand Tombal. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 805P) A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer (CRPC): results of PROSPER by age and region. Karim

• Fizazi. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3.

Lorlatinib: (Abstract 1380PD) Efficacy of lorlatinib in patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations. Benjamin J. Solomon. Friday, October 19. Session Type: Poster

• Discussion. Presentation Time: 14:00 – 15:00 CEST. Location: ICM – Room 14B.

(Abstract 1399P) Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). Solange Peters. Saturday, October 20. Session Type: Poster. Presentation Time: 12:30 – 13:30 CEST. Location: Hall A3. Palbociclib: (LBA2) Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. Massimo Cristofanilli. Saturday, October 20. Session Type: Proffered Paper. Presentation Time: 17:00 - 17:15 CEST. Location: Hall 2A – Room 18. (Abstract 338P) Real world treatment patterns associated with palbociclib combination therapy in Germany: results from the IRIS Study. Debanjali Mitra. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 332P) Clinical outcomes in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) with objective response (OR) or without

• bjective response (non-OR) in PALOMA-2. Hope S. Rugo. Monday, October 22. Session Type: Poster. Presentation

Time: 12:45 – 13:45 CEST. Location: Hall A3.

3

(Abstract 356P) A prospective observational study of mobile application-based patient-reported outcomes in advanced breast cancer: interim baseline data from the MADELINE study. Dawn Odom. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 344P) First report of real-world patient characteristics and treatment patterns from POLARIS: Palbociclib in hormone receptor-positive (HR+) advanced breast cancer – a prospective, multicenter, noninterventional study. Joanne L. Blum. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45

• CEST. Location: Hall A3.

(Abstract 334P) Health related quality of life in women with HR+/HER2- advanced or metastatic breast cancer treated in real world settings in Italy and Germany. Michelino De Laurentiis. Monday, October 22. Session Type:

• Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3.

Sunitinib: (Abstract 881P) Correlations between disease-free survival (DFS) and overall survival (OS) in patients with renal cell carcinoma (RCC) at high risk for recurrence: results from S-TRAC trial. Daniel J. George. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 916P) Sunitinib tolerance following an initial exposure period: results of longitudinal PRO data from S- TRAC study. Daniel J. George. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. Talazoparib: (Abstract 292O) Patient-reported outcomes (PRO) in patients with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib vs physician’s choice chemotherapy treatment (PCT): a focus

• n the EMBRACA triple negative (TNBC) subpopulation. Hope S. Rugo. Monday, October 20. Session Type: Proffered
• Paper. Presentation Time: 11:00 – 12:45 CEST. Location: Hall A2 – Room 18.

(Abstract 1567PD) Genetic testing of BRCA mutations in breast cancer across Europe: barriers and opportunities. Maia Thrift-Perry. Saturday, October 20. Session Type: Poster Discussion. Presentation Time: 9:15 – 10:30 CEST. Location: Hall B4 – Room 19. (Abstract 303P) EMBRACA: Comparison of efficacy and safety of talazoparib and physician's choice of therapy (PCT) in patients with advanced breast cancer (ABC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment. Miguel Martín. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 304P) EMBRACA: Efficacy and safety in comparing talazoparib with physician's choice of therapy (PCT) in patients with advanced breast cancer (ABC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis. Anthony Gonçalves. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45

• CEST. Location: Hall A3.

(Abstract 305P) Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase 3 EMBRACA trial. Yanke Yu. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3.

4

(Abstract 306P) Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in EMBRACA and ABRAZO trials. Mohamed Elmeliegy. Monday, October 22. Session Type:

• Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3.

(Abstract 307P) An international systematic review (SR) of breast cancer (BC) BRCA mutation (BRCAm)

• prevalence. Nigel Armstrong. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST.

Location: Hall A3. (Abstract 308P) Genetic screening, counselling, and treatment of BRCA mutation (BRCAm) carriers: a systematic review (SR) of international breast cancer (BC) guidelines. Carol Forbes. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 310P) Clinical outcomes, treatment patterns and health resource utilization (HRU) among metastatic breast cancer (mBC) patients with germline BRCA mutation (gBRCAm). Ruben Quek. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 432P) Population pharmacokinetic analyses for talazoparib in cancer patients. Yanke Yu. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. (Abstract 859TiP) TALAPRO-1: An open-label, response rate phase 2 study of talazoparib in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥1 novel hormonal therapy (NHT). Johann S. De

• Bono. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3.

Early-Pipeline Assets: OX40 (PF-04518600): (Abstract 1184P) Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs). Omid Hamid. Saturday, October 20. Session Type: Poster. Presentation Time: 12:30 – 13:30 CEST. Location: Hall A3. Pan-RCC: (Abstract 889P) Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors. Jeffrey Graham. Monday, October 22. Session Type: Poster. Presentation Time: 12:45 – 13:45 CEST. Location: Hall A3. ###